About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristant #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« United Cannabis Corp. v. Pure Hemp Collective Inc. (D. Colo. 2019) | Main | JMLS Program on ITC Practice »

April 26, 2019

Comments


An example of the negative media coverage of the pharma industry in the U.S.: Joe Nocera: "Why Big Pharma Is Winning the Drug Price Wars" (Bloomberg) [That report seems to even suggest marketing obfuscation and/or antitrust issues?]
Of patent concern, this kind of publicity seems likely to reduce the traditional pro-patent-law lobbying effectiveness of this industry.

Mr. Morgan,

Another example of "pro-patent" lobbying that reduces rather than benefits the overall view of patents can be seen in the Pharma efforts to eliminate or control natural secondary markets in the cross-border sense AFTER the patent holder has already achieved their benefit of a first sale - and the Big Pharma attempts to play a geographic sales game, which only make the average US citizen a de facto supporter of Big Pharma profit levels and artificially reduced prices in the foreign markets.

This aspect DOES circle back into the thread above, as Big Pharma allows itself to be negotiated INTO those "regulat[ed] drug prices by reference to an international index based on government-negotiated drug prices abroad" POSSIBILITY as is noted on a new post at: https://www.ipwatchdog.com/2019/04/28/accelerating-generic-entry-proven-solution-problem-prescription-drug-pricing/id=108586/

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.

Your Information

(Name is required. Email address will not be displayed with the comment.)

June 2019

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30